Combining interventional and systemic therapies for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how well combining interventional treatments (like chemoembolization) with systemic therapies (like targeted drugs and immunotherapy) works for liver cancer in real-life patients. The goal is to find which combinations work best for different people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- You have received or plan to receive interventional therapy (like chemoembolization) combined with systemic therapy (like targeted therapy or immunotherapy).
- You can provide your baseline health information and are willing to attend follow-up visits.
- You do not have another active cancer besides liver cancer.
- You are able to understand and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
This study tests a combination treatment for liver cancer that has not spread to other organs. It combines two procedures that deliver chemo directly to the liver (HAIC and TACE) with two medications (apatinib and camrelizumab) that help your immune system fight the cancer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.